NKTR Nektar Therapeutics
- 1.4200
- +0.0200+1.43%
- 1.4000
- -0.0200-1.41%
Nektar Therapeutics News
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Nektar Management to Present at Upcoming Investor Conferences
SAN FRANCISCO, May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare Conference in New York City
Nektar Files to Sell 25M Shares of Common Stock for Holders
J.P. Morgan Maintains Nektar Therapeutics(NKTR.US) With Sell Rating
J.P. Morgan analyst Jessica Fye maintains $Nektar Therapeutics(NKTR.US)$ with a sell rating.According to TipRanks data, the analyst has a success rate of 49.4% and a total average return of 4.3% over
Analysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)
Nektar Therapeutics(NKTR.US) 10% Shareholder Sells US$99,629.6 in Common Stock
$Nektar Therapeutics(NKTR.US)$ 10% Shareholder Deep Track Capital, LP sold 56,000 shares of common stock on May 10, 2024 at an average price of $1.7791 for a total value of $99,629.6. This transaction
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
Nektar Therapeutics | 10-Q: Quarterly report
Nektar Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Nektar Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Q1 2024 Nektar Therapeutics Earnings Call
Earnings Call Summary | Nektar Therapeutics(NKTR.US) Q1 2024 Earnings Conference
The following is a summary of the Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript:Financial Performance:Nektar ended Q1 with a cash balance of $326 million and anticipates to close 2
Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript
Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript
Nektar Therapeutics Q1 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $21.639M Beat $15.342M Estimate
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 73.97 percent increase over losses of $(0.
Nektar Therapeutics Q1 Loss Drops In Line With Estimates
Press Release: Nektar Therapeutics Reports First Quarter 2024 Financial Results
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO, May 9, 2024 SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported
Nektar Therapeutics 1Q Rev $21.6M >NKTR
Nektar Therapeutics 1Q Rev $21.6M >NKTR
Nektar Therapeutics Reports First Quarter 2024 Financial Results
SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securi
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based fin
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar
Analysis
Price Target
No Data
